[go: up one dir, main page]

DE60003791D1 - Felbamat-derivate - Google Patents

Felbamat-derivate

Info

Publication number
DE60003791D1
DE60003791D1 DE60003791T DE60003791T DE60003791D1 DE 60003791 D1 DE60003791 D1 DE 60003791D1 DE 60003791 T DE60003791 T DE 60003791T DE 60003791 T DE60003791 T DE 60003791T DE 60003791 D1 DE60003791 D1 DE 60003791D1
Authority
DE
Germany
Prior art keywords
felbamate
derivatives
felbamate derivatives
treat
epilepsy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60003791T
Other languages
English (en)
Other versions
DE60003791T2 (de
Inventor
L Macdonald
A Miller
D Thompson
M Dieckhaus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UVA Licensing and Ventures Group
University of Virginia UVA
Original Assignee
University of Virginia UVA
University of Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Virginia UVA, University of Virginia Patent Foundation filed Critical University of Virginia UVA
Publication of DE60003791D1 publication Critical patent/DE60003791D1/de
Application granted granted Critical
Publication of DE60003791T2 publication Critical patent/DE60003791T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/041,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/061,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • C07D263/24Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/041,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/061,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C07D265/081,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D265/101,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen atoms directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Iron (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hard Magnetic Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Paper (AREA)
DE60003791T 1999-02-09 2000-02-08 Felbamat-derivate Expired - Fee Related DE60003791T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11925499P 1999-02-09 1999-02-09
US119254P 1999-02-09
US13688199P 1999-06-01 1999-06-01
US13720499P 1999-06-02 1999-06-02
US137204P 1999-06-02
PCT/US2000/003147 WO2000047202A1 (en) 1999-02-09 2000-02-08 Felbamate derived compounds
US136881P 2008-10-10

Publications (2)

Publication Number Publication Date
DE60003791D1 true DE60003791D1 (de) 2003-08-14
DE60003791T2 DE60003791T2 (de) 2004-02-05

Family

ID=27382271

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60003791T Expired - Fee Related DE60003791T2 (de) 1999-02-09 2000-02-08 Felbamat-derivate

Country Status (13)

Country Link
US (3) US6538024B1 (de)
EP (1) EP1156798B1 (de)
JP (1) JP2002536409A (de)
AT (1) ATE244564T1 (de)
AU (1) AU771936B2 (de)
CA (1) CA2360258A1 (de)
DE (1) DE60003791T2 (de)
DK (1) DK1156798T3 (de)
ES (1) ES2197078T3 (de)
MX (1) MXPA01007968A (de)
NZ (1) NZ513319A (de)
PT (1) PT1156798E (de)
WO (1) WO2000047202A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001261219B2 (en) * 2000-05-05 2005-08-25 University Of Virginia Patent Foundation Felbamate derived compounds
WO2002056827A2 (en) * 2000-10-25 2002-07-25 University Of Virginia Patent Foundation Substituted felbamate derived compounds
US20030166648A1 (en) * 2002-11-01 2003-09-04 Macdonald Timothy L Felbamate derived compounds
PL1756225T3 (pl) 2004-06-08 2009-04-30 Lanxess Deutschland Gmbh Masy do formowania z poliamidów o polepszonej zdolności płynięcia
EP1992662B1 (de) 2004-06-08 2010-08-25 LANXESS Deutschland GmbH Formmassen auf Basis eines thermoplastischen Polyesters mit verbesserter Fließfähigkeit
PT1809273E (pt) * 2004-09-16 2010-05-10 Janssen Pharmaceutica Nv Utililização de 2-fenil-1,2-etanodiol-(di)carbamatos para tratamento de epileptogénese
AU2006240049A1 (en) * 2005-04-21 2006-11-02 Medpointe Healthcare Inc. Methods for synthesis of dicarbamate compounds and intermediates in the formation thereof
US20070021501A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods of treating epileptogenesis
DE102006020984A1 (de) * 2006-05-04 2007-11-08 Lanxess Deutschland Gmbh Leichtbauteil in Hybridbauweise
DE102007006493A1 (de) 2007-02-09 2008-08-14 Lanxess Deutschland Gmbh Leichtbauteil in Hybridbauweise
WO2009129181A1 (en) * 2008-04-14 2009-10-22 Concert Pharmaceuticals Inc. Propanediol-dicarbamate derivatives
DE102008032205A1 (de) 2008-07-09 2010-01-14 Lanxess Deutschland Gmbh Fließverbesserte Thermoplasten
DE102008058225A1 (de) 2008-11-19 2010-07-08 Lanxess Deutschland Gmbh Leichtbauteil in Hybridbauweise
DE202008015397U1 (de) 2008-11-19 2010-04-22 Lanxess Deutschland Gmbh Säulenstruktur
DE202008015398U1 (de) 2008-11-19 2010-04-08 Lanxess Deutschland Gmbh Ölwanne
DE202008015401U1 (de) 2008-11-19 2010-04-08 Lanxess Deutschland Gmbh Sitzstrukturen
DE202008015392U1 (de) 2008-11-19 2010-04-08 Lanxess Deutschland Gmbh Pedalstruktur
DE202008015396U1 (de) 2008-11-19 2010-04-08 Lanxess Deutschland Gmbh Fahrwerkstruktur
DE202008015399U1 (de) 2008-11-19 2010-04-08 Lanxess Deutschland Gmbh Dachstruktur
DE202008015391U1 (de) 2008-11-19 2010-04-22 Lanxess Deutschland Gmbh Türen- und Klappenstrukturen
DE102008058224A1 (de) 2008-11-19 2010-05-20 Lanxess Deutschland Gmbh Leichtbauteil in Hybridbauweise
DE202008015400U1 (de) 2008-11-19 2010-04-08 Lanxess Deutschland Gmbh Instrumententafel
DE202008015394U1 (de) 2008-11-19 2010-04-08 Lanxess Deutschland Gmbh Längsträgerstruktur
DE202008015395U1 (de) 2008-11-19 2010-04-22 Lanxess Deutschland Gmbh Vorderwagenstruktur
DE102009005763A1 (de) 2009-01-23 2010-07-29 Lanxess Deutschland Gmbh Rahmenseitenteil einer Kraftfahrzeug Karosserie
ATE522568T1 (de) 2009-03-27 2011-09-15 Lanxess Deutschland Gmbh Glühdrahtbeständige polyester
DE102009020090A1 (de) 2009-05-06 2010-11-11 Lanxess Deutschland Gmbh Reduktion des Einflusses der Wasseraufnahme auf die elektrische Leitfähigkeit von elektrisch leitfähigen Polyamid-Formmassen
DE102009034767A1 (de) * 2009-07-25 2011-01-27 Lanxess Deutschland Gmbh & Co. Kg Organoblechstrukturbauteil
US7964594B1 (en) * 2009-12-10 2011-06-21 Hoffmann-La Roche Inc. Amino oxazine derivatives
UA103272C2 (uk) * 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
DE102010053483A1 (de) 2010-12-04 2012-06-06 Lanxess Deutschland Gmbh =N=C=N- enthaltende Verbindung zur Verhinderung des thermischen Abbaus in Schmelzen
EP2365030B1 (de) 2010-03-10 2012-09-05 LANXESS Deutschland GmbH -N=C=N- enthaltende Verbindungen zur Verhinderung des thermischen Abbaus von Metall-dialkylphosphinat enthaltenden Polyalkylenterephthalaten in der Schmelze
PL2365028T3 (pl) 2010-03-10 2013-03-29 Lanxess Deutschland Gmbh Związki zawierające ugrupowania -N=C=N- do zapobiegania rozkładowi termicznemu poli(tereftalanów alkilenowych) zawierających dialkilofosfiniany metali w stopach
ES2433107T3 (es) 2010-12-13 2013-12-09 Lanxess Deutschland Gmbh Procedimiento para la optimización del comportamiento de cristalización de masas moldeables de poliéster
EP2465896A1 (de) 2010-12-14 2012-06-20 LANXESS Deutschland GmbH Polyester Zusammensetzungen
US20140178479A1 (en) * 2011-08-12 2014-06-26 Perosphere, Inc. Concentrated Felbamate Formulations for Parenteral Administration
EP2818297B1 (de) 2013-06-25 2016-08-10 LANXESS Deutschland GmbH Spritzgießverfahren
HUE032705T2 (en) 2013-11-27 2017-10-30 Lanxess Deutschland Gmbh Polyester compositions
ES2899882T3 (es) 2013-11-27 2022-03-15 Lanxess Deutschland Gmbh Uso de composiciones de poliéster
DE102014000613A1 (de) 2014-01-18 2015-07-23 Lanxess Deutschland Gmbh Polyester Zusammensetzungen
IN2014DE03298A (de) 2013-11-27 2015-09-25 Lanxess Deutschland Gmbh
DE102014000612A1 (de) 2014-01-18 2015-07-23 Lanxess Deutschland Gmbh Polyester Zusammensetzungen
EP2878625A1 (de) 2013-11-27 2015-06-03 LANXESS Deutschland GmbH Polyester Zusammensetzungen
EP2878630B1 (de) 2013-11-28 2019-11-20 LANXESS Deutschland GmbH Polyamidzusammensetzungen
EP2915841A1 (de) 2014-03-04 2015-09-09 LANXESS Deutschland GmbH Polyester Zusammensetzung
EP2942367B1 (de) 2014-05-05 2018-07-11 LANXESS Deutschland GmbH Polyester Zusammensetzungen

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2884444A (en) * 1956-01-13 1959-04-28 Carter Prod Inc 2-phenyl-1,3 propane diol dicarbamate
US4161582A (en) * 1976-11-22 1979-07-17 Hoffman-La Roche Inc. Process to produce oxazinomycin
US4384115A (en) * 1981-12-14 1983-05-17 The Dow Chemical Company Process for preparing tetrahydro-1,3-oxazin-2-ones
US4868327A (en) 1987-06-03 1989-09-19 Carter-Wallace, Inc. Synthesis of 2-phenyl-1,3-propanediol
US4978680A (en) 1989-09-26 1990-12-18 Carter-Wallace, Inc. Method for the prevention and control of epileptic seizure
US5082861A (en) 1989-09-26 1992-01-21 Carter-Wallace, Inc. Method for the prevention and control of epileptic seizure associated with complex partial seizures
US5292772A (en) 1989-09-26 1994-03-08 Carter-Wallace, Inc. Method for the prevention and control of epileptic seizure associated with Lennox-Gastaut syndrome
US5055489A (en) 1990-05-04 1991-10-08 Carter-Wallace, Inc. Method for the prevention and control of hypoxic damage resulting from cerebral ischemic events
AU5159393A (en) * 1992-09-18 1994-04-12 Schering Corporation Process for preparing felbamate, 2-phenyl-1,3-propanediol and intermediates
US5462966A (en) 1993-10-15 1995-10-31 Carter-Wallace Inc. Methods for the prevention and control of cellular damage resulting from coronary artery occlusion-reperfusion
US5492930A (en) * 1994-04-25 1996-02-20 Schering Corporation Method and formulation for treating CNS disorders
US5728728A (en) 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection

Also Published As

Publication number Publication date
ES2197078T3 (es) 2004-01-01
EP1156798A1 (de) 2001-11-28
ATE244564T1 (de) 2003-07-15
US20030229086A1 (en) 2003-12-11
EP1156798A4 (de) 2002-07-17
DE60003791T2 (de) 2004-02-05
US6538024B1 (en) 2003-03-25
DK1156798T3 (da) 2003-11-03
EP1156798B1 (de) 2003-07-09
JP2002536409A (ja) 2002-10-29
US6599935B2 (en) 2003-07-29
US6759402B2 (en) 2004-07-06
PT1156798E (pt) 2003-11-28
WO2000047202A1 (en) 2000-08-17
AU771936B2 (en) 2004-04-08
AU2873400A (en) 2000-08-29
US20020156070A1 (en) 2002-10-24
NZ513319A (en) 2003-08-29
MXPA01007968A (es) 2003-07-14
CA2360258A1 (en) 2000-08-17

Similar Documents

Publication Publication Date Title
DE60003791D1 (de) Felbamat-derivate
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
ECSP003610A (es) Pirimidina-2,4,6 trionas inhibidores de metaloproteinas
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ES2119124T3 (es) Bencimidazoles utiles para el tratamiento de trastornos del sistema nervioso.
TR199901904T2 (xx) 3-piridil enantiyomerleri ve bunlar�n analjezik olarak kullan�lmas�.
TR200401545T4 (tr) NOSS inhibitörü ilaçların amalatı için ikame imidazo [1,2-a]piridin-,-pirimidin- ve-pirazin-3-amin-türevlerinin kullanımı
PA8481301A1 (es) Derivados de 4,4-biarilpiperidina
DE60027564D1 (de) Tek-antagonisten
UY26130A1 (es) Compuestos para tratar la obesidad
ES2168359T3 (es) Acido micofenolico 6-sustituido y derivados con actividad inmunosupresora.
EA200701782A2 (ru) Производные азаспироалканов в качестве ингибиторов металлопротеаз
MXPA04006184A (es) Compuestos derivados de 1h-pirazolilo, para el uso en enfermedades asociadas con el receptor 5-ht2c.
CR6824A (es) Derivados de arilmetilamina para uso como inhibidores de triptasa
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
DE60016181D1 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
ES2064119T3 (es) Nuevos derivados de aminobenzosultam como inhibidores de la lipoxigenasa.
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
ECSP003590A (es) Compuestos calcioliticos
CA2362833A1 (en) Phenylalaninol derivatives
ES2118248T3 (es) Esteres y amidas de 9-cloro-prostaglandina y su empleo para preparar medicamentos.
BR0015404A (pt) Compostos relacionados com ácido 15-hidroxieicosatetraenóico e métodos de uso
MXPA03003677A (es) Compuestos derivados de felbamato sustituidos.
TWI262791B (en) 6-methoxy-2-naphthylacetic acid prodrugs

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee